Trial
NCT02951156
Avelumab In Combination Regimens That Include An Immune Agonist, Epigenetic Modulator, CD20 Antagonist and/or Conventional Chemotherapy in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL)
Phase IIITERMINATEDEFFICACY/FUTILITYConfidence: HIGH
Sponsor
Pfizer
Collaborators
EMD Serono
Condition
Diffuse Large B-Cell Lymphoma
Intervention
Avelumab
Why stopped
Study was terminated due to closure of study arms following futility analysis and difficulty in enrolling participants due to evolving treatment landscape
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2020-12-17